

## Special Issue

# Nano-Based Drug Delivery and Drug Discovery

### Message from the Guest Editor

Nanotechnology involves the manipulation and utilization of materials, devices, and systems at the nanometer scale. This rapidly evolving field presents numerous opportunities and a wide array of applications across engineering, medicine, and life sciences. Nanotechnology shows promise as the preferred platform for drug delivery when addressing the challenges of conventional medications used in the treatment and management of various diseases and developing innovative treatment and diagnostic approaches. Potential topics include, but are not limited to, the following:

- Drug targeting and release (nanoparticles functionalization and optimization, and stimuli-responsive targeting and releasing).
- Multiple drug administration (multifunctional nanoparticles, combination nanomedicines, personalized nanomedicine, theragnostic nanoparticles, and sequential drug release).
- Nanocarriers in drug delivery (design and optimization of nanocarriers, and the role of nanocarriers in drug delivery).
- Smart drug delivery system and its clinical potential.
- Applications of nano-based systems for drug delivery.

---

### Guest Editor

Dr. Xiangli Shao

Department of Chemistry, The University of Texas at Austin, Austin, TX, USA

---

### Deadline for manuscript submissions

closed (31 December 2025)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/202710](https://mdpi.com/si/202710)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).